Kyverna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	-	-	7.03
Gross Profit	-	-	-	7.03
Selling, General & Admin	35.7	30.13	12.48	8.01
Research & Development	135.93	112.47	49.92	28.4
Total Operating Expenses	171.63	142.6	62.41	36.41
Operating Income	-171.63	-142.6	-62.41	-29.38
Interest Income	13.12	15.36	2.28	0.57
Interest Expense	-0.1	-0.14	-0.19	-0.07
Other Non-Operating Income (Expense)	0.09	0.09	0.06	0.01
Total Non-Operating Income (Expense)	13.11	15.31	2.15	0.51
Pretax Income	-158.52	-127.3	-60.26	-28.88
Net Income	-158.7	-127.48	-60.37	-28.89
Net Income to Common	-158.7	-127.48	-60.37	-28.89
Shares Outstanding (Basic)	43	38	1	0
Shares Outstanding (Diluted)	43	38	1	0
Shares Change (YoY)	154.17%	5590.81%	47.89%	-
EPS (Basic)	-3.54	-3.33	-89.61	-63.43
EPS (Diluted)	-3.54	-3.33	-89.61	-63.43
Free Cash Flow	-142.05	-116.46	-53.03	-36.88
Free Cash Flow Per Share	-3.29	-3.04	-78.73	-80.97
Gross Margin	-	-	-	100.00%
Operating Margin	-	-	-	-418.28%
Profit Margin	-	-	-	-411.03%
FCF Margin	-	-	-	-525.00%
EBITDA	-169.49	-140.47	-60.7	-28.33
EBITDA Margin	-	-	-	-403.32%
EBIT	-171.63	-142.6	-62.41	-29.38
EBIT Margin	-	-	-	-418.28%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q